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Abstract
Background: Although early presentation to HIV-care is essential to ensure timely initiation of antiretroviral therapy,
recent studies have shown that especially migrants present to HIV-care at a later stage of HIV-infection. Currently, thirty
percent of all newly diagnosed HIV cases in Germany originate from abroad. So far it is unknown, which specific migrant
groups in Germany are particularly at risk for late presentation to HIV-care.
Methods: We used data from the Clinical Surveillance of HIV Disease (ClinSurv) cohort, a multi-centre observational
cohort (01/01/1999 and 31/07/2013) and included treatment-naïve patients with valid information on country of origin
and date of enrolment. Migrants were patients with country of origin outside Germany. We compared time trends for
percentage of AIDS (CDC Stage C) and mean CD4-count at enrolment between migrants from Western Europe (WE),
Central Europe (CE), Eastern Europe (EE), Sub-Saharan Africa (SSA), South East Asia (SEA) and non-migrants using
multivariable regressions. Male non-migrants with mean age of 38-years constituted the reference group.
Results: In total, 10,211 patients fulfilled the inclusion criteria, of which 2784 were migrants (SSA: 42%, CE: 17%, WE: 11%,
EE: 10%, SEA: 9%). The percentage of patients with AIDS at enrolment was higher in SSA (Odds Ratio (OR)SSA: 1.44, 95%-
confidence interval (95%-CI):1.12–1.84) and SEA-migrants (ORSEA:2.16, 95%-CI:1.43–3.27). In addition, female SEA-migrants,
were more likely to present with AIDS than their male counterparts (OR:2.22, 95%-CI:1.18–4.17). Mean CD4-count at
enrolment was lower for SSA- (Mean CD4-count ratio (IRR):0.72; 95%-CI:0.64-0.82) and SEA-migrants (IRR:0.62, 95%-CI:0.49-0.
78). Over time, it increased in non-migrants and CE-migrants (by 1 and 3%/year, respectively), whereas no increase was
seen for SEA and SSA.
Conclusions: SSA and SEA-migrants in Germany present to HIV-care at a later stage of HIV infection than non-migrants.
Additionally, previous research found a higher risk for late HIV-testing for migrants. Collecting information about the arrival
date of migrants in Germany in the HIV notification system would help to understand to which extent these problems
could be tackled in Germany. Moreover, participatory approaches for HIV-testing and care as well as research regarding
knowledge, behaviour and attitudes towards these topics for SSA and SEA migrants should be expanded.
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Background
According to the latest International Migration Report of
the United Nations, there are over 200 million migrants
worldwide, of which 10 million reside in Germany [1].
In Europe between 2007 and 2012, 40% of the cases of
Human Immunodeficiency Virus (HIV) reported to the
European Centre for Disease Prevention and Control
(ECDC), originated from a country outside the country
where their HIV infection was diagnosed [2]. In both
reports migrants are defined as foreign-born or, when
country of birth was not available, foreign citizens. In the
German notification data on new HIV-diagnoses informa-
tion on country of birth or citizenship is not collected.
Hence migrants are defined by country of origin, namely
as cases, which have spent the majority of their life time
outside Germany. From 2002 to 2013, around 30% of new
HIV-diagnoses in Germany are seen in migrants [3].
Generally, HIV-testing in Germany is offered free-of-
charge. In addition, anonymous testing is possible at most
local public health voluntary counselling and testing sites
and at several non-governmental organizations. HIV-
testing for pregnant women and patients with suspected
HIV-infection at the general practitioners and specialists
is covered by statutory health insurances [4].
German-Austrian antiretroviral treatment (ART) guide-
lines for HIV-infection for adults recommended that ART
should be initiated in all symptomatic patients especially
after the onset of at least one illness defining acquired im-
munodeficiency syndrome (AIDS) [5, 6]. Furthermore,
they also consider CD4 T-cell counts of below 350 CD4
cells/μl as a threshold for treatment indication, since
ART was found more beneficial regarding a decelerated
progression to AIDS and death when initiated at higher
CD4-counts [7, 8]. Currently, worldwide HIV research
societies discuss an update of national HIV-treatment
guidelines to recommend ART-initiation irrespective of
CD4-cell count. This is a consequence of recently pub-
lished results of the Strategic Timing for Anti-Retroviral
Treatment (START) Trial showing benefits regarding
HIV-outcomes in patients timing ART-initiation at CD4-
counts >350 cells/μl over patients with deferred treatment
initiation [9, 10].
ART in Germany is offered to all HIV-positive patients.
It is fully paid by statutory health insurance, which postu-
lates treatment by specialized physicians [11]. In order to
enable timely initiation of ART according to guidelines, an
early presentation of HIV-positive patients to HIV-care is
essential.
Past studies on clinical features in migrants in Germany
have already shown an association of migration status with
late presentation for HIV-care [12]. However, the present
study aims to analyse late presentation to HIV-care with
regards to different groups of migrants. In this context, we
compared the percentage of patients presenting with
AIDS, as well as the CD4-cell count at entry to special-
ized care among different migrant populations and
non-migrants in a long term cohort study of HIV posi-
tive patients in Germany.
Methods
Data source
We used data from the Clinical Surveillance of HIV
Disease (ClinSurv) cohort. This open multi-centre long
term observational cohort was established on 1st January
1999 and is a network of 15 HIV treatment centres and
university clinics in major German cities, which collect
data on about 19.000 HIV-positive patients (as of 31 July
2013) with unknown date of HIV-infection. For each
patient who seeks care in a participating centre, informa-
tion on age, sex, country of origin (collected by the treat-
ing physician according to patient’s information) and
transmission group category was reported at enrolment
in ClinSurv. Clinical parameters (such as occurrence of
opportunistic diseases, Centers for Disease Control and
Prevention (CDC) stage, immunological and virological
status (viral load and CD4 T-cell count) of HIV infection
as well as information on ART (date of initiation, com-
bination of drug classes in therapy regimes, therapy
interruption) are recorded upon enrolment and updated
for every date in which the patient visits the centre after
enrolment. The collected data is sent biannually in an
encrypted format to the Robert Koch Institute, where it
undergoes verification and quality checks [13]. The
Robert Koch Institute is the German national public
health institute; therefore the Federal Commissioner for
Data Protection is the responsible entity for studies con-
ducted by the Robert Koch Institute. Information on
HIV infection collected in ClinSurv corresponds to the
data reported to the RKI according to legal requirements
implemented by the national Protection against Infec-
tion Act (IfSG) of 2001. All patient data collected in
ClinSurv are generated during routine care. The German
Federal Commissioner for Data Protection therefore
waived the need for ethical approval for the ClinSurv
study. No written informed consent is required from
patients.
The ClinSurv cohort collects anonymized data on all
HIV-patients, who are in medical care in these 15 partici-
pating centres.
Authors from the Robert Koch Institute, as the data
processing site, only had access to anonymized data and
had no access to identifying information. All data analyses
were performed on the anonymized data set. There were
no permissions required to conduct scientific analyses.
For our analysis we extracted all entries of patients
enrolled in ClinSurv between 1 January 1999 and 31 July
2013, who were older than 15 years and treatment naïve
at enrolment in ClinSurv and where the definite time of
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enrolment into ClinSurv was known. Furthermore, only
patients, where sex and country of origin were available
in the database were included. We excluded patients
who acquired HIV-infection through haemophilia,
mother-to-child-transmission or by occupational expos-
ure (rare transmission routes).
Definitions
As described above, a migrant was defined as a patient
with a reported country of origin outside Germany.
Migrants were further categorized in migrant groups
by regions of origin according to the World Health
Organization (WHO) region definitions [14].
AIDS was defined by CDC Stage C diagnosis. Here the
date of diagnosis before enrolment or within 45 days after
enrolment was classified as presenting with AIDS at enrol-
ment into the cohort. We obtained the CD4-count in
cells/μl of a patient when presenting to specialized care by
using the CD4-count measured at the enrolment of the
patient into ClinSurv.
Statistical analysis
In order to get an overview of the study population, we
analysed the most frequent regions of origin for mi-
grants descriptively. For non-migrants and migrants by
region of origin, the median age, percentage of males,
most frequent risk groups and mean CD4-counts and
proportion of patients with AIDS were compared. We
performed rank sum and Chi-squared tests to test for
differences in sex and age at ART-initiation between mi-
grants overall and non-migrants.
We performed multivariable regressions to estimate the
difference in CD4-count and percentage of patients with
AIDS prior to enrolment into ClinSurv between non-
migrants and the five most frequent migrant groups. The
other migrant regions, which were represented by less
than 200 enrolled patients over the timespan 1999 to
2013, were excluded from the regression models. Instead
of the continuous age variable used in the descriptive ana-
lysis, for the regression analysis, age groups (in 10 year in-
tervals) were formed in order to consider also non-linear
effects of age. Regarding CD4-count we performed
negative binomial regressions including only patients
with available information on CD4-count at their enrol-
ment visit. The obtained incidence rate ratios (IRR) in
our model refer to the mean CD4 count ratio. IRR were
calculated with their 95%-confidence intervals (95%-
CI). In the negative binomial regression, the variance
can be estimated through the dispersion parameter. To
compare the percentage of patients with AIDS, odds ra-
tios (OR) and their 95%-CI were analysed in logistic re-
gressions. In addition a time-variable was included in
the regression models, to describe the trends of these
values over the time period 01/01/1999 to 31/07/2013.
Male non-migrants in the age group 35–44 years (which
included the median age of this subgroup) constituted the
reference group. An alpha of 0.05 was considered the level
indicating statistical significance.
All analyses were performed with the software STATA
14.0.
Results
Of 19,256 patients enrolled in the ClinSurv cohort as of
31/07/2013, 10,211 patients fulfilled the inclusion cri-
teria (see Fig. 1 for details). Of those, 2784 (27%) were
migrants. The majority of migrants (42%) originated
from Sub-Saharan Africa (SSA), followed by Central
Europe (CE, 17%), Western Europe (WE, 11%), Eastern
Europe (EE, 10%) and South-East Asia (SEA, 9%). Rare
regions of origin were amongst others Latin America,
and the Middle East and North-Africa Region with 5 and
3%, respectively (see Fig. 2).
Migrants overall enrolled in the cohort at a significantly
younger age (median age: 34 years) than non-migrants
(median age: 38 years) (p-value: <0.001) and were less often
male (60% versus 88%, respectively) (p-value: <0.001).
While Western and Central Europeans show a more simi-
lar distribution of these characteristics to non-migrants,
migrants from Eastern Europe display the lowest age at
enrolment. Migrants from Sub-Saharan Africa are least
frequently male (39%).
Non-migrants, Western Europeans and migrants from
Central Europe acquired HIV-infection predominantly
via the Men-who-have-sex-with-men (MSM)-transmis-
sion route (64%, 61% and 45%, respectively). For mi-
grants from Eastern Europe, Injecting drug use (IDU) as
Fig. 1 Study population and excluded patients from ClinSurv
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a transmission route was noticeably higher (27%) com-
pared to other migrant regions (see Table 1).
AIDS
In non-migrants and migrants from Western Europe,
Central Europe and Sub-Saharan Africa approximately
15% of patients join ClinSurv after AIDS is present. For
migrants from South-East Asia this percentage is elevated
(27%) (see Table 1). In the multivariable analysis, among
male patients, migrants from Sub-Saharan Africa and
South-East Asia were more likely to enrol after diagnosis
of AIDS compared to non-migrants (ORSEA: 2.16, 95%-
CI:1.43 – 3.27; ORSSA: 1.44, 95%-CI: 1.12 – 1.84). Overall
no difference in AIDS at enrolment between male and
female patients was found, except for South East Asian
migrants, where females are more likely to present with
AIDS to specialized care than their male counterparts
(OR = 2.22, 95%-CI:1.18–4.17) (see Table 2).
Over time, a consistent decrease in percentage of pa-
tients enrolling in the cohort with AIDS-diagnosis is seen
in male patients of all groups. However, this decreasing
time trend is not visible for female patients. (See Table 2
and Fig. 3a and b). For migrants from Eastern Europe the
proportion of patients with linkage to care after AIDS-
diagnosis is significantly lower (6%) than for non-migrants
and all other migrant groups, as not only descriptive but
also regression analysis show (OREE = 0.52, 95%-CI: 0.30 –
0.69; see Table 1 and 2).
CD4-count
CD4-count at enrolment was available for a total of 9080
of the 9320 patients of the migrant groups of interest. In
descriptive analyses, mean CD4-count at enrolment was
lower in the Central European, Sub-Saharan African and
South East Asian migrants than in non-migrants, while
for migrants from Eastern Europe a higher CD4-count is
seen (see Table 1). Using 35 to 44-year old, male non-
migrants as reference, regression analysis showed a lower
mean CD4-count at enrolment for migrants from Sub-
Saharan Africa (IRR: 0.72; 95%-CI: 0.64 - 0.82) and South-
East Asia (IRR: 0.62, 95%-CI: 0.49 - 0.78) (see Table 3).
Fig. 2 Region of origins of migrants (n = 2784) in the study
population, 1999–2013
Table 1 Characteristics of the study population at enrolment, 1999–2013, (n = 9320; only selected migrant groups shown)
Characteristic at enrolment Non-Migrants Western Europe Central Europe Eastern Europe Sub-Sahara Africa South-East Asia
Total number of patients 7,427 307 463 280 1,167 263
Median Age (in years);
(interquartile range)
38 (31–45) 37 (31–44) 34 (29–42) 31 (26–37) 33 (28–39) 33 (28–39)
Sex
Female; n (%) 890 (12) 33 (11) 85 (18) 110 (39) 708 (61) 127 (48)
Male; n (%) 6537 (88) 274 (89) 378 (82) 170 (61) 459 (39) 136 (52)
Transmission Group; n (%)
MSM 4,724 (64) 187 (61) 209 (45) 62 (22) 22 (2) 72 (27)
IDU 610 (8) 29 (9) 41 (9) 76 (27) 7 (0.60) 6 (2)
Hetero 1,348 (18) 50 (16) 151 (33) 94 (34) 3 (0.26) 31 (12)
High prevalence country (HPC)a – 7 (2) 5 (1) 6 (2) 1,135 (97) 133 (51)
Unknown 745 (10) 34 (11) 57 (12) 42 (15) – 21 (8)















aTransmission group HPC (High prevalence country): origin from a high prevalence country for HIV-infection, when other transmission group category is unknown.
A high prevalence country is defined as a country with an adult HIV infection prevalence of >1% [14]
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From 1999 to 2013 mean CD4 count at enrolment in-
creased by 1%/year (95%-CI: 1%–2%) for non-migrants
and 3%/year (95%-CI: 1%–5%) for migrants from Central
Europe. For all other migrant groups, no significant trend
is visible (see Table 3, Fig. 4).
Discussion
Zoufaly et al. previously used ClinSurv to investigate char-
acteristics of late presentation for HIV care [12]. They
showed that migration status constitutes a risk factor for
late clinical presentation (AIDS prior to the first visit in a
ClinSurv centre or CD4-count lower than 350 cells/ul) to
HIV care centres. As migrant groups in Germany are het-
erogeneous in their formation and underlying risk factors
for HIV-infection, it is important that this present study
managed to disentangle Zoufaly et al.’s captured differ-
ences in regards to different migrant groups. Our results
identified, that especially HIV-positive migrants from
Sub-Saharan Africa and South-East Asia are linked to
specialized care at a later stage of HIV infection than
non-migrants. The risk of presentation to HIV-care
with AIDS-diagnosis is elevated in these groups com-
pared to non-migrants. For female migrants from
South-East Asia, this increased risk is in particular
alarming. From 2008 onwards, German treatment
guidelines recommend initiation of ART at higher CD4-
levels [5, 6] This might be an explanation for the ob-
served overall decrease in the proportion of patients
presenting to specialized care with AIDS from 1999 to
2013 in our cohort. Why this decrease is lacking to be
observed for female patients of all groups, needs to be
further explored, especially since all patient groups irre-
spective of their sex have found to be linked to care at
increasingly higher CD4-counts over time in our study
population. Mean CD4-counts of South-East Asia and
Sub-Saharan African migrant groups at linkage to care
were identified to be lower than for non-migrants and
Western European migrants. For migrants from South-
East Asia, the mean CD4-counts at first contact to special-
ized care were found below 300 cells/μl throughout the
whole study period, which makes initiation of treatment at
below 350 cells/ul according to guidelines challenging.
In line with this, a few very recent studies in Europe
captured the decreased CD4-count of certain migrant
groups (from the Asian continent and the Sub-Saharan
African region) compared to native populations at initi-
ation of ART [15, 16]. Parallel to this, when analysing
the presentation of different migrant populations to
ART initiation, the German ClinSurv cohort showed
similar elevated risks for Sub-Sahara African and South
East Asia migrants. We did not investigate, whether as
a possible consequence of this presentation to care and
ART-initiation after presence of AIDS or with low CD4-
counts, further clinical outcomes or accelerated death
occured in our cohort.
To get an insight in the population of people living with
HIV in Germany at point in time previous to linkage to
HIV-care, namely the first HIV-test in Germany, Zoufaly
et al. performed additional analysis of German HIV sur-
veillance data in addition to the ClinSurv analysis [12]. It
provides case-based data on every new-diagnosed case of
HIV through notification by the diagnosing laboratories.
However, as HIV surveillance data lacks information on
clinical and immunological parameters for many cases
and is not linkable to the ClinSurv cohort, this additional
method was not applied to our research on different
migrant groups. Nevertheless, Zoufaly et al.'s findings
showed that migrants also present late for HIV-testing in
Table 2 Multivariable logistic regression model for time trend
of percentage with AIDS at enrolment, 1999–2013 (n = 9907);
significant results in bold
Percentage with AIDS prior to enrolment OR 95%-CI p-value
Region of origin of migrant group
Non-migrants Ref. – –
WE 0.90 0.70–1.39 0.952
CE 1.20 0.90–1.60 0.222
EE 0.52 0.30–0.96 0.038
SSA 1.44 1.12–1.84 0.004
SEA 2.16 1.43–3.27 <0.001
Sex
Male Ref. –
Female 1.17 0.81–1.67 0.403
Sex and Region of origin, (2013)
Female WE 0.55 0.12–2.43 0.428
Female CE 0.49 0.20–1.21 0.122
Female EE 1.39 0.50–3.83 0.526
Female SSA 1.02 0.69–1.51 0.916
Female SEA 1.90 1.05–3.46 0.035
Age Group (in years)
15–24 0.31 0.23–0.42 <0.001
25–34 0.67 0.58–0.78 <0.001
35–44 Ref. – –
45–54 1.57 1.34–1.83 <0.001
55+ 1.90 1.57–2.30 <0.001
Time trend (per year) by sex;
1999–2013
Female 0.99 0.96–1.03 0.742
Male 0.94 0.93–0.96 <0.001
Percentage with AIDS prior to
enrolment
Odds 95%-CI p-value
(reference group, 2013) 0.12 0.10–0.14 <0.001
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Germany. This could possibly constitute a contributing
factor for later linkage to care of the migrant populations
seen in our analysis. In this context, evidence on migrants’
late presentation for HIV-testing in Europe has been ex-
tensive in the past [17–20]. Particularly the African
migrant population has been found particularly at risk for
late HIV-testing [21, 22]. One study found a delayed
testing of this migrant group, but observed an uptake of
HIV-care similar to non-migrants [23].
Results of participatory research at the Robert Koch
Institute among migrants from Sub-Saharan Africa in
Germany (MiSSA) show that migrants of this group
were often not aware of the anonymous and free HIV-
testing offer or assumed that a positive HIV-test will
impact their legal status in the country [24]. These
together with the fear of stigmatization of HIV-positive
migrants in their communities have constituted barriers
to HIV testing in African migrants in the past [22, 25–28].
These identified barriers underline our interpretation that
migrants from this group may refrain more frequently
from HIV testing.
In contrast to other migrant groups, Eastern European
migrants present to care at an earlier stage of HIV-
infection than non-migrants in terms of AIDS and mean
CD4-count. A reason for this could be that a large part
of the HIV-infections in the Eastern European migrant
population in Germany is acquired via IDU and MSM
transmission. For those risk groups HIV-testing is especially
promoted in Germany. Other migrant groups, such as
South-East Asian migrants and Sub-Sahara African mi-
grants consist of females, predominantly infected by hetero-
sexual transmission – risk groups, who are not especially
targeted for HIV-testing. This fact underlines once more
the importance of accounting for the different composition
of migrant groups in terms of HIV.
According to a recent review on HIV-testing policies in
Europe, the German HIV-testing framework, although
acknowledging migrants as a vulnerable group for HIV
has so far neither issued a tailored recommendation for
migrants for HIV-testing within the HIV-testing strategy
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Fig. 3 Logistic regression model for time trend of percentage with AIDS at enrolment stratified by sex, 1999–2013; a Non-migrants and migrants
from Eastern Europe, b Migrants from Sub-Saharan Africa and South East Asia; only selected migrant groups shown
Zeitlmann et al. BMC Infectious Diseases  (2016) 16:739 Page 6 of 9
RKI conducted first efforts to establish guidelines for a
more tailored HIV-testing framework for migrants in
Germany in the MiTest-Study between 2014 and 2015
[30]. This mixed-method research included focus group
discussions and surveys of cultural mediators, physicians
and other staff at HIV-test centres in seven German cities.
As a result, useful outreach approaches for certain mi-
grant groups in Germany, such as visiting asylum seeker
centres, women’s groups and religious assemblies for HIV
testing information could be identified. The study fur-
thermore reports young South-East Asian women as a
subgroup of migrants with particularly limited access to
HIV-test offers due to their lack of essential knowledge
on HIV, which could be an attributable factor explaining
our findings.
The legal and political framework for migrants in
Germany, the complex composition of the migrant pool
in Germany, the lack of more need-adapted testing
offers and culture-related factors (such as lack of HIV
knowledge and feared stigmatization) nevertheless still
form barriers for migrants’ HIV-test seeking uptake,
according to the study.
However, when interpreting our results some limita-
tions must be considered.
The majority of migrants recorded in the ClinSurv
cohort are covered by statutory health insurance and
have regular access to the health care system in Germany.
As a consequence, the study population lacks information
regarding the proportion of migrant people with AIDS
symptoms without any access to the German health care
system (for example undocumented migrants). The pro-
portion of AIDS among this group might be higher than
observed in our study collective.
Secondly, small sample sizes of certain migrant groups
for example the number of enrolled Eastern European mi-
grants in the cohort, make interpretation of the results for
these particular subgroup only possible with caution.
Table 3 Multivariable negative binomial regression modela for
mean CD4-count enrolment into ClinSurv, 1999–2013 (n = 9080);






Region of origin of migrant group
Non-migrants Ref. – –
WE 0.94 0.75–1.16 0.551
CE 0.97 0.83–1.14 0.733
EE 0.84 0.68–1.03 0.092
SSA 0.72 0.64–0.82 <0.001
SEA 0.62 0.49–0.78 <0.001
Age Group (in years)
15–24 1.37 1.28–1.46 <0.001
25–34 1.12 1.08–1.17 <0.001
35–44 Ref. – –
45–54 0.88 0.83–0.92 <0.001
55+ 0.78 0.73–0.84 <0.001
Sex
Male Ref. –
Female 1.07 1.02–1.13 0.007
Time trend (per year) by
region of origin, 1999–2013
Non-migrants 1.01 1,01–1.02 <0.001
WE 1.01 0.98–1.03 0.509
CE 1.03 1.01–1.05 0.008
EE 0.97 0.94–1.00 0.065
SSA 1.01 1.00–1.02 0.139
SEA 1.01 0.99–1.04 0.367
Mean CD4-count (cells/ul)
at enrolment
Incidence rate 95%-CI p-value
(reference group) 2013 383 365–403 <0.001
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Fig. 4 Negative binomial regression model for timely trend in mean CD4 count at enrolment, 1999–2013, only selected migrant groups shown
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Last, no information is available about the arrival date
of the migrants in Germany and also no documented in-
formation about the first HIV test of the patients. There-
fore no conclusions about HIV disease progression since
arrival in Germany can be drawn out of the cohort data.
As past evidence and current recommendations illustrate,
it would be helpful to include information about migrants’
arrival date in Germany into HIV-notification system to
close this interpretation gaps in the future [31, 32]).
Conclusions
In conclusion, we show that particularily migrants from
Sub-Saharan Africa and South-East Asia in Germany
enter HIV-care at a later stage of HIV infection than
non-migrants. This may be a result of late presentation
for HIV-testing, as previous research indicates. Collect-
ing information about the arrival date of migrants in
Germany in the HIV notification system would help to
understand to which extent this problem could be tack-
led in Germany.
In order to reduce the proportion of late presentation
among those migrants groups, the existing participa-
tory approaches for HIV-testing and care should be fur-
ther strengthened. It is important to disentangle even
more the heterogeneous group of migrants, to identify
which particular groups still remain unreached by those
approaches and identify their specific community organi-
zations in Germany. This opens the door for implementa-
tion of knowledge attitude, behaviours and practice
studies - similar to the research performed within migrant
groups from Sub-Saharan Africa in Germany (MiSSA) -
for further migrant groups aiming to develop new tailored
strategies, which will improve these groups’ access to
HIV-testing and care.
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